WASHINGTON, Aug. 4-Medicare is about to announce that beginning in October it will start paying hospitals for use of the thrombolytic drug tissue plasminogen activator (tPA) for treatment of ischemic ...
These words uttered in 1901 relate directly to studies of thrombolytics for AMI. In GISSI-1 and 2 other major thrombolysis trials, the investigators did not require an informed consent of the patients ...
Reteplase appears to be another safe and effective thrombolytic option for the treatment of acute ischemic stroke, according to results from the randomized RAISE trial. When given within the first 4.5 ...
COLUMBUS, Ohio--(BUSINESS WIRE)--Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy, today announced that the first patients have ...
Responding to a recently released American College of Chest Physicians evidence-based clinical practice guidelines for antithrombotic and thrombolytic therapy (.pdf), EKOS® Corporation from Bothell, ...
Overall, 5.7% of participants with MCI had 1-year risk for any indication for anticoagulant and thrombolytic drugs. (HealthDay News) — A considerable proportion of adults with mild cognitive ...
A silicon-based nanothrombolytic combines clot dissolution with local microenvironment regulation, enhancing safety and efficacy in thrombotic disorders. (Nanowerk News) Thrombotic disorders—such as ...
Thrombotic disorders—such as ischemic stroke, heart attack, pulmonary embolism, and deep vein thrombosis—are principal contributors to global mortality. However, conventional thrombolytic therapies ...
The proof of efficacy of thrombolysis for acute myocardial infarction (AMI) depends on 9 randomized placebo-controlled trials totaling 58,511 patients. The meta-analysis of these trials showed an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results